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1. Introduction
Annually, approximately 43,140 people are diagnosed (incidence 10-12/100000) with pancre‐
atic ductal adenocarcinoma (PDAC) in the United States and the mortality rate of 36800 almost
equals this number [1]. PDAC ranks fourth on the list of cancer-related causes of death and
despite extensive scientific and clinical effort, the prognosis of this exceptionally lethal disease
has not improved significantly over the past decades [2]. Surgical resection, for which only a
minority (less than 20%) of the patients qualify due to late diagnosis in advanced stages, is
currently the only chance of cure, improving 5-year survival rates from <4% if left untreated
to 20-30% after resection [3]. Unresectable tumors are characterized by early invasion and
metastases as well as by an extreme chemoresistance. Despite subtle progress over the years
in terms of therapeutic strategies in many malignancies, no major conventional treatment
options have come forward from numerous clinical trials in pancreatic cancer.
Considering its bad prognosis much effort was put into revealing the hidden secrets of
pancreatic cancer that explain the severity of this disease. Among the different fields of tumor
biology in pancreatic cancer research, this chapter will focus on the morphological and
molecular features that cause and accompany pancreatic carcinogenesis.
2. Morphological features of pancreatic carcinogenesis
Although there was little improvement in pancreatic cancer treatment during the past decades,
much effort has been made in understanding the pathogenesis of pancreatic cancer. In contrast
to its rapid progress after diagnosis, recent published data clearly show that the clonal
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evolution of the earliest alterations in cancer initiating cells towards frankly invasive and
metastasized PDAC takes at least more than a decade [4, 5]. This creates an important window
of opportunity for early detection and much effort is put into attempts to map the molecular
and morphological changes resulting in pancreatic cancer formation.
The current model of pancreatic carcinogenesis describes a stepwise process from healthy
acinar cells to frank pancreatic adenocarcinoma: Recent lineage-tracing studies have shown
that acinar cells harboring molecular alterations are induced to transdifferentiate, generating
duct-like cells through a process known as acinar-to-ductal metaplasia (ADM) [6]. ADM
lesions then convert to precancerous pancreatic intraepithelial neoplasia (PanIN) that progress
to PDAC over time [7]. PanIN lesions are found in the smaller pancreatic ducts and are
classified in four grades based on the degree of dysplasia reflected in the cytonuclear atypia
and architectural change of the epithelial cell: PanIN-1A, -1B, -2 and -3 [7]. The lowest grade
PanIN lesions can be flat (-1A) or papillary (-1B), but are characterized by absence of nuclear
atypia and retained nuclear polarity. PanIN-2 lesions show micropapillary features with
evidence of nuclear atypia and infrequent mitoses. PanIN-3 lesions demonstrate all hallmarks
of cancer, including a widespread loss of polarity, nuclear atypia and frequent mitoses and are
considered as Carcinoma in situ [1, 8]. Yet, the lesion is confined within the basement membrane
and no invasive growth is present. The increasing grades of dysplasia in the various PanIN
lesions manifest the morphological steps of tumor progression that precede invasive PDAC.
These consecutive steps of tumor progression are accompanied by a cumulative occurrence of
molecular alterations.
3. Molecular characteristics of pancreatic carcinogenesis
3.1. Genetic alterations in pancreatic carcinogenesis
For many decades pancreatic cancer was described as an exclusively genetic disease. In 2008
Jones and colleagues discovered 1561 somatic gene mutations within more than 20000
analyzed genes, yielding an average rate of 63 genetic abnormalities per pancreatic cancer,
emphasizing the extreme complexity of this disease [9]. These genetic alterations can be
clustered in 12 partially overlapping signaling pathways (compare Fig. 1). Five of the pathways
comprise specific cellular functions: apoptosis, DNA-damage repair, G1/S phase cell cycle
progression, cell-cell adhesion and invasion.
Apoptosis or programmed cell death, plays an essential role in carcinogenesis since resistance
to apoptosis is a key factor of the survival of a cancer cell [1]. In PDAC, genes implicated in
the apoptosis pathway (Bcl2, Mcl-1, p53, NF-kB among others) were found altered in all tumors
studied and many reports document impaired apoptotic signaling in this disease [10, 11]. For
example, a high fraction of apoptotic cells has been correlated with longer overall survival as
well as absence of nodal involvement [12]. Moreover, resistance to chemotherapeutics is mostly
a result of defective apoptosis pathways.
DNA damage control genes code for proteins that repair any damage that occurs in the cell
during its lifespan and thus are responsible for safeguarding the integrity of DNA [1]. For
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instance, the BRCA2 protein is involved in DNA damage repair, especially after occurrence of
interstrand brakes [13]. Germline BRCA2 gene mutations are responsible for approximately
10% of familial pancreatic cancers [14]. Mismatch repair family (MMR) genes target base
substitution mismatches as well as intersection deletions that arise as a result of errors
occurring regularly during replication. Alterations in these mismatch repair genes lead to
genetic instability and make the genome vulnerable for additional, more severe genetic
alterations [15].
One of the most important and best studied proteins involved in DNA damage repair is the
tumor suppressor protein p53. p53 is responsible for the cellular response to genotoxic stress
as it mediates apoptosis and cell cycle arrest [16]. p53 is frequently disrupted in many human
malignancies and the tumor suppressor is lost in 50-75% of PDACs [17].
Cell cycle regulation and progression is affected in virtually all transformed pancreatic cells.
Enhanced activation of genes promoting G1/S-phase transition or loss of cell cycle inhibitors
results in uncontrolled cell division which facilitates tumor progression and unrestrained
tumor growth [1].
In normal pancreatic tissue, cells are anchored to each other and their surroundings via
multiple connections. A decrease in these interactions can allow cells to detach from their
surroundings and allows transformation, migration and metastasis. As such, cell to cell
adhesion and interaction plays an important role in carcinogenesis [18, 19].
The other pathways discovered by Jones and colleagues which proofed to be frequently
affected by genetic alterations in pancreatic cancer are signaling cascades that can be divided
into three groups: embryonic signaling pathways, MAPKinase signaling pathways and TGFß-
signaling pathways [9]. The transforming growth factor ß (TGFß) pathway has been linked to
PDAC for many years. TGFß signaling is involved in a wide range of cellular processes
including differentiation, proliferation, apoptosis and angiogenesis [20]. As discussed in detail
later in this chapter, TGFß signaling functions as a double-edged sword as it comprises tumor-
suppressive as well as oncogenic qualities.
All MAPK signaling pathways consist of the same basic kinase components. Stimulation of an
upstream MAP2K kinase by growth factors, stress or other extracellular signals leads to
phosphorylation of one of the terminal MAPK: extracellular signal-regulated kinase (Erk), c-
Jun N-terminal kinase (JNK) or p38 [8]. These signaling cascades result in the activation of
multiple oncogenic cellular functions.
One growth factor receptor responsible for many signaling events in early carcinogenesis is
the Epidermal Growth Factor Receptor (EGFR). EGFR is located in the cell membrane and is
activated by binding of its specific ligands, including epidermal growth factor (EGF) and
Transforming Growth Factor alpha (TGFα) [6, 21]. Upon activation, EGFR undergoes dimeri‐
zation, thus stimulating its intrinsic intracellular protein-tyrosine kinase activity resulting in
autophosphorylation of several tyrosine residues in the C-terminal region of the receptor. This
autophosphorylation elicits activation of numerous downstream kinases and signal transduc‐
tion cascades that modulate cancer associated phenotypes as cell proliferation, migration and
adhesion [6]. Recent work has proven a high impact of EGFR signaling on induction of
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pancreatic metaplasia, and overexpression of the receptor already occurs in early pancreatic
precursor lesions [6, 21]. The relevance of EGFR dependent signal cascades was emphasized
by a therapeutic beneficial effect of the EGFR inhibitor Erlotinib in a subgroup of pancreatic
cancer patients [22].
Since embryogenesis shares many characteristics with carcinogenesis, not surprisingly many
embryonic pathways are involved in tumor development. The three embryonic pathways
operative in pancreatic carcinogenesis are the Hedgehog-, Notch- and Wnt-signaling cascades
[9]. Several studies have shown upregulation of these pathways during pancreatic carcino‐
genesis and in invasive pancreatic cancer and their inhibition results in decreased tumor
proliferation and enhanced apoptosis [1]. For instance, activation of the Notch signaling
pathway is involved in cell proliferation and angiogenesis in a variety of human cancers,
including pancreatic cancer [23]. Notch signaling is initiated when Notch ligand binds to its
receptor between adjacent cells. Upon activation, Notch is cleaved and releases the Notch
intracellular domain (NICD) via a cascade of proteolytic enzymes including Y-secretase.
Finally, NICD translocates into the nucleus and activates its target genes such as Hes-1, Hey-1,
Cyclin D1 and cMyc [24]. Additional to its growth promoting functions accumulating evidence
shows a molecular link between Notch and epithelial-to-mesenchymal transition (EMT) in
pancreatic cancer [25]. During the EMT process, epithelial cells gain a mesenchymal phenotype
accompanied by the cumulative expression of the mesenchymal markers Vimentin, Slug, Snail
and ZEB1 and reduced expression of the epithelial marker E-cadherin. EMT-type cells harbor
an increased migratory and invasive capacity resulting in invasion and spread of tumor cells
even during early carcinogenesis [26]. Inhibition of Notch-signaling leads to reduction of EMT
resulting in a better clinical outcome [25].
Similar to Notch-signaling, the hedgehog pathway belongs to the developmental programs of
pancreatogenesis. The hedgehog gene was originally identified in Drosophila when a large-
scale screening for mutations revealed an altered segmentation pattern of larvae, resulting in
a short, fat larva covered in a “lawn” of denticles resembling a hedgehog [27]. Early in
development, around embryonic day 8.5-9.0, the hedgehog ligands Indian Hedgehog (Ihh)
and Sonic hedgehog (Shh) are expressed throughout the endodermal epithelium of the
primitive gut but are noticeably absent in the developed organ [28]. Sonic hedgehog signaling
is reactivated in the case of pancreatic regeneration, for example in response to inflammation-
associated pancreatic injury [29]. Through inappropriate activation of these pathways, chronic
injury might contribute to misdirection of tissue repair, ultimately resulting in neoplasia.
Aberrant expression of members of the hedgehog-pathway in chronic pancreatitis and
pancreatic carcinogenesis was first noted by Kayed and colleagues [30]. Subsequent research
proved that the ligand Shh is expressed aberrantly in pancreatic cancer and its precursor
lesions and that Shh functions as a mediator of cancer initiation and growth [31]. Mice with
transgenic misexpression of Shh in the pancreatic endoderm develop lesions resembling
PanIN, and hedgehog inhibition induces apoptosis and blockes proliferation in pancreatic
cancer cells in vivo and in vitro [31]. Thus, hedgehog signaling can be described as an early and
late mediator of pancreatic ductal adenocarcinoma.
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Conceptually, these data suggest that pancreatic cancer is substantially a disease of pathways.
But research into these pathways rendered clearly that these cascades must ultimately engage
the function of epigenetic regulators to influence gene expression in a heritable manner. Thus
studies into epigenetics in pancreatic cancer demonstrate a logical extension to the genetic
paradigm of this malignant disease.
ʏ
Signaling pathway Affected genes 
Apoptosis p53, NF-ƙB, PI3K/Akt 
DNA damage repair p53, BRCA2, MMR-genes 
G1/S transition p16Ink4a, p14arf, p15Ink4b, Cyclin D 
Regulation of invasion TGFß, Integrin signaling 
Embryonic signaling Notch, Hedgehog, Wnt 
MAPK signaling Erk, Jnk, p38 
TGFß signaling TGFß, Smad-proteins 
Figure 1. The commonly altered signaling pathways in PDAC accompanied by affected genes from these path‐
ways (adopted from [1]).
4. Epigenetic mechanisms in pancreatic carcinogenesis
Epigenetics are defined as any heritable genomic mechanism unrelated to changes in the DNA
sequence [32]. Epigenetic modifications are involved in normal cellular development and
maintenance, but they are also responsible for deregulation of gene expression, resulting in
diseased cellular phenotypes. Most notably, deregulation of epigenetic mechanisms can
contribute to cancer development [33-38]. The past years have witnessed an explosive increase
in our knowledge about epigenetic features in pancreatic carcinogenesis. Several well-known
epigenetic mechanisms are active in pancreatic cancer, sub-divided into DNA methylation,
histone modification and microRNAs, all of them affecting the cell by induction or suppression
of gene expression [39-42]. For instance, the introduction of genome-wide screening techniques
has accelerated the discovery of a growing list of genes with abnormal methylation patterns
in the transforming pancreatic epithelial cell that play a role in the neoplastic process [43].
Hypermethylation of promoter cytosine-phospho-guanine (CpG) islands is closely linked to
gene silencing and loss of tumor suppressor function in many cancer entities [44]. Since the
first detailed analysis of DNA hypermethylation in pancreatic cancer was reported in 1997 by
Schutte et al., many tumor-suppressor or cancer-related genes that undergo aberrant methyl‐
ation during pancreatic cancer development have been identified, including APC, RUNX3,
SOCS-1, p16Ink4a, Cyclin D2 and CHD13 [44, 45].
By influencing the structure of chromatin, in addition to DNA methylation, posttranslational
modifications of histone tail residues highly affect the transcriptional activity of genes. While
acetylation of histones is primarily associated with transcriptional activation, methylation of
histones can lead to both, activation and repression, depending on the modified residue [46,
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47]. For instance, Polycomb proteins, which are known for their crucial role in induction of
repressive histone modifications, embody oncogenic properties in many human cancers.
Polycomb proteins can be divided into two functional biochemical categories, Polycomb
repressive complexes (PRC) 1 and 2. While members of the PRC 2 complex initiate gene
repression by catalysation of H3K27 trimethylation, proteins belonging to PRC1 maintain the
repressive state [48, 49]. Under physiological conditions, the activity of Polycomb proteins is
crucial in development as well as in maintenance and proliferation of pluripotent progenitor
cells in a variety of tissues. Overexpression of these proteins may promote tumorigenesis by
fostering a self-renewing population of cells [50, 51]. Indeed, overexpression of Polycomb
proteins is responsible for malignant progression and poor prognosis in breast [52], bladder
[53] and prostate [54] cancer and shows strong association with hallmarks of cancer, including
induced cellular proliferation [55], angiogenesis [56], survival [57] and migration [58].
Enhancer of Zeste Homolog 2 (EZH2) is the only PRC2 protein member thus far studied in
pancreatic cancer. Strong nuclear accumulation of EZH2 was found in 55% of well differenti‐
ated tumors and 98% of poorly differentiated samples in a comprehensive immunohistochem‐
ical analysis of PDACs, indicating a significant correlation between EZH2 expression and
dedifferentiation in pancreatic cancer [59]. Additionally, EZH2 overexpression participates in
epithelial-to-mesenchymal transition (EMT) and invasion through repression of epithelial
proteins like E-cadherin [60].
The third group among the epigenetic players in pancreatic carcinogenesis comprises the
MicroRNA (miRNA) family, a class of small non-protein coding RNAs which participate
in post-transcriptional control of gene expression in eukaryotic organisms [61]. In the last
years, advanced global screening technologies have enabled large scale analyses of miRNA
profiles  in  diverse  tissue  samples,  indicating  that  miRNAs can  function  as  either  onco‐
genes  or  tumor  suppressors  in  the  development  of  various  cancer  types,  including
pancreatic cancer [62, 63]. The analysis of miRNA expression patterns has let to complete‐
ly  novel  insights  into  pancreatic  cancer  biology.  Specific  miRNAs,  such  as  the  miR-200
family, miR-34a and miR-155 are involved in PDAC-biology by regulating genes associat‐
ed with metastasis and cell stemness [64, 65].
The era of epigenetics in pancreatic cancer has emerged strongly within the last years and
deepened our understanding of pancreatic cancer biology. One of the most important charac‐
teristics of epigenetic mechanisms which clearly demarcates them from genetics is their
reversibility. This feature provides new targets for novel therapeutic interventions in pancre‐
atic cancer and other epithelial tumors.
The manifold genetic and epigenetic events observed in pancreatic carcinogenesis mirror the
complexity of this malignancy and lead to the assumption that targeting one molecular feature
of pancreatic carcinogenesis is not sufficient for successful pancreatic cancer treatment.
Though inaccessible for therapeutic options, there exists at least one molecular event found in
virtually all invasively growing pancreatic tumors and their precursor lesions: The constitutive
activation of oncogenic Kras probably demonstrates the most important and best studied event
in pancreatic carcinogenesis.
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5. Impact of Kras activation on pancreatic carcinogenesis
The mutation of Kras belongs to the earliest events in pancreatic carcinogenesis. Kras proteins
comprise a family of signal-transducing GTPases that mediate a wide variety of cellular
functions including proliferation, differentiation and survival and are frequently mutated in
human cancers [66]. Although Kras is a GTPase, its intrinsic activity is inefficient and requires
GTPase activating proteins to promote GTP hydrolysis and attenuate downstream signaling
[1]. Oncogenic mutation of Kras (KrasG12D) is generally accepted to represent the initial key
event in pancreatic carcinogenesis and found in virtually all invasively growing pancreatic
tumors [7]. Due to its prominent role in pancreatic carcinogenesis Kras is considered to be an
attractive therapeutic target of PDAC-treatment, but specific biochemical properties of the
protein have made this an elusive goal [67]. Activating Kras point mutations at codon 12 (from
GGT to GAT or GTT and more rarely CGT) result in substitution of glycine with aspartate,
valine or arginine. Oncogenic Kras mutations lock the protein in its GTP-bound form thus
permitting its constitutive interaction with and activation of multiple effectors, independent
on growth factor stimulation [67].
The activation of Kras engaged effector pathways, like the RAF-mitogen-activated kinase
(MAPK)-cascade, phosphoinositide-3-kinase- (PI3K) signaling and the Ral GDS pathway
results in stimulation of proliferation, invasion, metastases and survival thus enabling
pancreatic cancer progression [3]. Given the aforementioned limitations in Kras inhibition,
these downstream targets may provide alternative effective points of therapeutic intervention
and thus are the focus of ongoing studies in pancreatic specific systems.
The impact of constitutive Kras activation is not limited on the epithelial cell but also partici‐
pates in the modulation of the tumor environment. One hallmark of PDAC is an extensive
stromal remodeling, the most prominent features of which are the recruitment of inflammatory
and mesenchymal cells as well as fibrotic replacement of pancreatic parenchyma [68]. Recent
studies revealed that even early stages of PanIN development are associated with a stromal
reaction, which is characterized by a robust desmoplastic response and recruitment of immune
cells. Subclasses of these immune cells, immature myeloid cells, suppress infiltrating T cells
and thus establish an immune privilege in the tumor microenvironment promoting pancreatic
carcinogenesis [69, 70]. Mechanistically, constitutive activation of Kras in pancreatic ductal
cells triggers the production of the cytokine GM-CSF, which, in turn, promotes the expansion
of immunosuppressive myeloid cells, leading to the evasion of CD8+ T-cell-driven-antitumor
immunity [69, 70].
Due  to  its  high  biological  relevance  for  pancreatic  carcinogenesis,  a  genetically  engi‐
neered mouse model (GEMM) with pancreas specific Kras mutation was created,  allow‐
ing detailed investigations of morphological as well as molecular features of this disease
[71]. This transgenic mouse model bares a mutation of the endogenous murine Kras gene
specifically in pancreatic progenitor cells by crossing mice with a conditionally activated
Kras allel (LSL-KrasG12D)  to transgenic strains that express Cre recombinase in pancreatic
lineages (PdxCre or p48Cre). These “KC” mice develop low and high grade PanIN lesions
recapitulating pancreatic carcinogenesis in the human situation but only slowly progress
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to  PDAC  at  an  advanced  age  [71].  This  mouse  model  taught  us  that  in  spite  of  the
requirement  of  Kras-activation for  pancreatic  cancer  development oncogenic  Kras  muta‐
tion  alone  fails  to  transform precursor  lesions  into  invasive  cancer  due  to  activation  of
powerful fail-safe mechanisms (compare Fig. 2).
Counteracting transformation and growth, cellular senescence, a permanent cell growth arrest,
is increasingly recognized as one of the most critical fail-safe programs in pancreatic carcino‐
genesis [72]. A major cause of this permanent growth arrest was found in telomeres, which are
non-coding nucleoprotein complexes positioned in the extremes of chromosomes [73]. During
successive cellular divisions, telomeres in normal human cells shorten progressively and,
when telomeres erode down below a threshold length, the cell ceases to divide itself and
becomes senescent. Importantly, senescence can also be observed in the absence of any
detectable telomere shortening or dysfunction in numerous conditions such as cellular stress
or oncogene activation. Oncogene induced senescence (OIS) has emerged as a powerful tumor
suppressor mechanism protecting cells from unrestrained proliferation imposed by oncogenic
signaling [74]. It has been proven that normal cells, when forced to express high levels of
oncogenic Ras, undergo a permanent and irreversible cell cycle arrest [75]. OIS is frequently
found in premalignant lesions but is essentially absent in advanced cancers, suggesting that
malignant tumor cells can find ways to bypass or escape senescence [76].
Pancreas specific expression of oncogenic KrasG12D promotes an initial burst of proliferation
accompanied by the development of PanIN precursor lesions before cells stop dividing. These
precursor lesions then exhibit many features of senescence including positive senescence-
associated ß-galactosidase staining and induction of cell cycle inhibitors [77]. Successful
progression of PanIN lesions towards frank adenocarcinoma requires evasion from senes‐
cence. This can result from additional genetic or epigenetic events concerning major tumor
suppressor pathways, namely the p19Arf-p53 pathway and the p16Ink4a-Rb cascade [74].
6. Role of tumor suppressor inactivation in pancreatic carcinogenesis
The p53 protein plays a central role in modulating cellular responses to cytotoxic stress by
contributing to both, cell cycle arrest and programmed cell death [3]. Signals of mitogenic
oncogenes, such as cMyc or Kras lead to activation of p53, which depending on cell type and
stimulus induces either apoptosis or senescence and consequently leads to the elimination of
cells with oncogenic activation. p53 is integrated in a complex network of upstream sensors
and downstream effectors. An important sensor of oncogenic signals for p53 is p19Arf, which
is encoded in an alternative reading frame (ARF) by the tumor suppressor locus CDKN2A [78].
Activation of p19Arf antagonizes the effect of the E3 ubiquitin ligase MDM2 that acts upon p53
to initiate its proteasomal degradation, thereby contributing to the stabilization of the tumor
suppressor gene [74]. In the nucleus, stabilized p53 binds to promoters of more than 300 target
genes with implications for cell growth control. One such important p53 downstream target
is p21. p21 binds to and inhibits the activity of Cyclin-CDK2 and Cyclin-CDK1 complexes and
thus functions as a negative regulator of cell cycle progression at the G1 phase [79].
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In agreement with its key role in senescence and tumor suppression, mutational p53 inacti‐
vation is associated with accelerated carcinogenesis in many tumor entities [80]. In the
pancreas, p53 inactivation on chromosome 17 has been reported in 50-75% of carcinomas [1].
In the murine pancreas carcinoma model, genetic loss of p53 allows Kras to bypass senescence
resulting in 100% penetrance at an early age, thus recapitulating human PDAC including
histopathological similarities in neoplastic cells, desmoplasia and occurrence of liver and lung
metastases [81].
Figure 2. Current model of pancreatic carcinogenesis: on the background of Kras mutation ADM lesions progress
to PanIN-precursor lesions and invasive carcinoma depending on additional signals as loss of tumor suppressor func‐
tion or activation of inflammatory pathways. A: Acinar-ductal metaplasia, B: PanIN-1, C: PanIN-2-3, D: Invasive pancre‐
atic cancer.
The p16Ink4a gene, located on the short arm of chromosome 9, is one of the most frequently
inactivated tumor suppressor genes in pancreatic cancer [1, 2]. Remarkably, virtually all
pancreatic carcinomas bare loss of p16Ink4a function, in 40% of pancreatic cancer through
homozygous deletion, in 40% by intragenic mutation coupled with loss of the second allele,
and in 15% by hypermethylation of the p16Ink4a gene promoter [8].
The protein p16Ink4a belongs to the cyclin D-dependent kinase (CDK) inhibitor family and
functions to prevent the phosphorylation of Rb-1 by CDK 4 and 6, resulting in a blockage of
G1/S-phase transition of the cell cycle [82]. This event is a decisive step in the inhibition of cell
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cycle progression and also in senescence initiation. In contrast to that, loss of p16Ink4a results in
inappropriate phosphorylation of Rb-1, thereby facilitating progression of the cell cycle
through enhanced G1/S transition [1-3, 74].
Additional to inactivation of tumor suppressor genes, Kras-initiated pancreatic carcinogenesis
can be promoted by signals from the inflammatory environment [69, 70]. This type of proin‐
flammatory environment can be provided by chronic pancreatitis, the most relevant risk factor
for PDAC development in human [83]. Chronic pancreatitis supports the initiation and
progression of this malignancy by direct modification of gene expression networks in pancre‐
atic epithelial cells. For instance, pancreatitis contributes to tumor progression by abrogating
the senescence barrier characteristic of low-grade PanIN lesions [84]. Most importantly,
chronic pancreatitis induces a wide range of proteins, predominantly inflammatory transcrip‐
tion factors. The majority of these inflammatory transcription factors inhabits oncogenic
potential, mediated by inhibition of tumor suppressor genes or synergism with KrasG12D
signaling to promote pancreatic carcinogenesis.
By introducing the inflammatory family of Nuclear factor of activated T cells (NFAT) proteins,
the following part of the chapter will cite an example how deregulated oncogenes participate
in and cooperate with KrasG12D mediated signaling in every single step of pancreatic carcino‐
genesis, beginning from induction of ADM over progression of pancreatic precursor lesions
to frank invasive pancreatic ductal adenocarcinoma.
6.1. NFAT proteins and their role in pancreatic carcinogenesis
6.1.1. The family of NFAT transcription factors and their cellular regulation
The NFAT family, first described as a regulator of T cell activation and differentiation,
comprises four calcium-responsive isoforms named NFATc1, NFATc2, NFATc3 and NFATc4
as well as a more distant relative, NFAT5 [85]. In resting cells, NFAT factors are located in the
cytoplasm in a highly phosphorylated, inactive state [85, 86]. Ligand binding to many receptors
results in the activation of phospholipase C (PLC), the release of IP3 and in a transient release
of Ca2+ from intracellular stores through IP3 receptors. This initial release of Ca2+ demonstrates
the prerequisite for increased influx of Ca2+ through specialized Ca2+ released activated
channels (termed CRAC) [86]. CRACs provide the persistent Ca2+ signal that is necessary for
sufficient activation of the phosphatase calcineurin that targets and dephosphorylates
moderately conserved serine rich motifs in the N-terminal homology region of NFAT proteins
to unmask its nuclear localization signals [87]. Subsequently, NFAT proteins shuttle into the
nucleus where they are either ubiquitinated for HDM2-dependent proteasomal degradation
or stabilized by GSK3ß-mediated phosphorylation (compare Fig. 3) [88]. Upon stabilization
the transcription factor recognizes its GGAAA consensus sequence within target gene
elements and binds DNA either as homodimer or heterodimer [85-88]. In fact, NFAT proteins
frequently cooperate with other transcription factors to elicit high-affinity binding on common
target genes. GATA Proteins, FoxP3 and members of the MEF family are only few among a
wide range of NFAT partner proteins [89]. Additionally, NFAT recruits other signaling
regulated transcription factors (e.g. Smad3 and NKkB) to integrate pathway specific signals to
Pancreatic Cancer - Insights into Molecular Mechanisms and Novel Approaches to Early Detection and Treatment12
Ca2+/calcineurin regulated transcription [90]. Thus, NFAT transcription complexes function as
signal integrators and detectors. One signal has to be Ca2+/calcineurin, while the second one
can have developmental origin or can embody oncogenic qualities as the Ras-MAP kinase
pathway [89, 90]. Doing so, the cooperation between NFAT and its partners helps controlling
the specificity of NFAT target gene binding and the resulting mode of action.
Figure 3. NFAT signaling in pancreatic cancer. Upon Ca2+ - dependent activation of Calcineurin, NFAT becomes de‐
phosphorylated and shuttles into the nucleus. The calcineurin-inhibitor Cycosporin A (CsA) prevents NFAT activation.
In the nucleus GSK3ß-dependent phosphorylation of NFAT either leads to its nuclear export or allows binding to tar‐
get genes in association with partner transcription factors. Ubiquitination of NFAT proteins labels them for proteoso‐
mal degradation by HDM2.
7. Oncogenic potential of NFAT signaling
The NFAT family of transcription factors was originally identified as a group of inducible
nuclear proteins which regulate transcription during T lymphocyte activation [91]. Following
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their initial discovery, a multitude of studies quickly established that NFAT proteins are also
expressed outside the immune system where they participate in the regulation of the expres‐
sion of genes influencing cell growth and differentiation [86]. One of the first studies impli‐
cating NFAT factors in cell proliferation was performed in fibroblasts, in which constitutively
active NFATc1 induces cell transformation and colony formation [92]. Similarly, in pancreatic
tumor cells proliferation and anchorage-independent growth is - at least in part - dependent
on calcineurin activity and nuclear translocation of NFAT proteins [93]. This is consistent with
high levels of nuclear NFAT in pancreatic cancer cells and in particular in those cells with
accelerated growth. Nowadays, ectopic activation of NFAT members is recognized as an
important aspect of oncogenic transformation in several human malignancies, most notably
in pancreatic cancer [88, 93]. Proliferation and anchorage-independent growth of cultured
pancreatic cancer cells is significantly attenuated by inhibition of Ca2+/Calcineurin signaling
with Cyclosporin A or siRNA-technology-mediated depletion of NFATc1 [94]. Besides
proliferation and growth, NFAT proteins incorporate additional features of tumor biology.
Being downstream mediators of α6ß4 integrin signaling NFATc2 and NFAT5 promote cancer
invasion in breast and colon cancer [95]. Stimulation of angiogenesis through upregulation of
VEGF and enhancement of tumor cell migration via transcriptional activation of Cox2 are
additional oncogenic features of NFAT proteins [86, 96].
GEMM with constitutive activation of NFATc1 revealed increased cellular proliferation in
pancreata of young mice but mice baring a constitutive activation of NFATc1 failed to develop
advanced PanIN lesions within a one-year observations span. In contrast to mice bearing an
isolated transgenic induction of NFATc1, mice carrying combined constitutive activation of
Kras and NFATc1, a situation found in 70% of human PDACs, surprise with a dramatically
shortened survival compared to the KrasG12D animals [Baumgart et al., unpublished data].
Further resembling human PDAC, KrasG12D;NFATc1 mice develop severe cachexia and
abdominal distension caused by the accumulation of sanguineous ascites and bile duct
obstruction. At necropsy, the pancreata from KrasG12D;NFATc1 mice are enlarged by tumor
mass, which contains both solid and cystic regions. Notably, pancreata from KrasG12D;NFATc1
mice express nuclear NFATc1 throughout carcinogenesis and at equivalent levels to those
observed in human PDAC.
Beyond doubt, the experience with the described transgenic mouse model which recapitulates
human PDAC disease in a very accurate manner clearly shows that activation of NFAT
proteins works synergistically with Kras signaling and leads to acceleration of pancreatic
carcinogenesis. Further investigations shot light on the NFAT dependent mechanisms
facilitating and hastening pancreatic carcinogenesis.
8. NFATc1 function in ADM
The cellular origin of PDAC has been a controversial topic for many decades. PDAC has long
been considered to be a disease of pancreatic ducts. However, early efforts to model the disease
by forcing Kras expression in pancreatic duct cells did not yield discernable pathology [97]. In
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recent years, increasing evidence arised that PanIN precursor lesions and invasive PDAC
originate from differentiated acinar cells. The development of duct-like PanIN lesions from
acinar cells requires massive remodeling of these cells, both morphologically and with respect
to gene expression profiles. The transition from acinar to ductal cell properties has been termed
acinar-to-ductal metaplasia (ADM) and lineage tracing experiments have confirmed that this
process is a result of direct transdifferentiation from adult acinar cells that convert to a ductal
phenotype upon expression of constitutive active Kras [97, 98]. In murine and in human
samples, ADM development has been shown to precede PanIN formation, suggesting that
ADM represents the first step of pancreatic carcinogenesis.
Appreciating the relevance of ADM for pancreatic cancer development, much effort was
put into research on the molecular mechanisms facilitating ADM. As a transcription factor
that is  involved in differentiation processes in many tissues NFAT constitutes a promis‐
ing candidate to mediate ADM. Indeed, NFATc1 is highly operative in pancreatic ADM,
while only rare expression of the transcription factor can be found in acinar cells. In vitro
and in  vivo  studies  have  revealed  that  KrasG12D  driven  ADM requires  ligand-dependent
activation of the Epidermal growth factor receptor [6, 21]. Careful molecular studies have
proven that EGFR signaling – at least in part – is mediated via NFATc1. Most important‐
ly, in spite of active EGFR signaling, pharmacological or genetic inactivation of NFATc1 in
acinar cell explants extracted from KrasG12D mice reduces duct formation in vitro. Further‐
more,  KrasG12D  mice harboring a pancreas specific transgenic inactivation of NFATc1 are
less susceptible to inflammation induced ADM and show a significant delay of pancreatic
carcinogenesis  [unpublished  data].  These  findings  clearly  indicate  a  key  role  of  NFAT
signaling in the initial steps of pancreatic carcinogenesis.
9. NFATc1 and STAT3 cooperation in pancreatic carcinogenesis
Recent investigations established that NFATc1 cooperates with the signal transducer and
activator of transcription-3 (STAT3) [Baumgart et al., unpublished data]. Like NFAT proteins,
STAT3 is also regulated primarily at the level of its subcellular localization [90]. In resting cells,
STAT3 resides in a non-phosphorylated version in the cytoplasm. However, following
cytokine or growth factor stimulation, STAT3 proteins are inducibly phosphorylated on critical
regulatory tyrosine residues promoting their homodimerization and subsequent translocation
into the nucleus where they control gene transcription [99]. Interestingly, genetic depletion of
STAT3 attenuates the transformation capacity of NFATc1, suggesting a cooperative function
of both transcription factors in pancreatic cancer. From the mechanistic point of view, NFATc1
interacts with STAT3 to form enhancer-promoter communications at jointly regulated genes
involved in inflammation and oncogenesis, e.g. EGFR and Wnt-family members. The NFATc1-
STAT3 transcription pathway is operative in pancreatitis-mediated carcinogenesis as well as
in established human pancreatic cancer [Baumgart et al., under review].
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10. Impact of NFAT proteins on the inflammatory tumor environment
Cancer-associated inflammation plays an important role in restraining anti-tumor immunity,
particularly in pancreatic cancer for which a massive infiltration of immunosuppressive
leukocytes into the tumor stroma is an early and consistent event in carcinogenesis [84]. In
contrast to many other solid tumors, intratumoral T cells are rare in pancreatic cancer, which
is associated with an immune escape and bad prognosis [70]. In PDAC, increasing evidence
suggests, that oncogenic Kras drives an inflammatory program that establishes immune
privilege in the tumor microenvironment [69, 70]. The immune surveillance of pancreatic
cancer demonstrates the response to signals from the transformed epithelial pancreatic cell.
Cytokines like GM-CSF are secreted by ductal pancreatic cells to modulate the inflammatory
tumor environment. Recent work suggests an essential role of NFAT proteins in the transcrip‐
tional induction of a core of cytokines associated with encapsulation of the transformed cell
from physiological immune response [100, unpublished data]. Thus, NFAT inactivation might
represent a promising possibility to restore pancreatic cancer response to tumor suppressive
immune signals.
11. NFAT mediated TGFß switch from tumor suppressor to oncogene in
pancreatic carcinogenesis
As mentioned above, an emerging model in cancer biology supports a dual role for TGFß
signaling in tumorigenesis, acting as a tumor suppressor in early carcinogenesis and as a strong
promoter of cell proliferation, migration and invasion in advanced tumor stages [101, 102].
TGFß blocks cell proliferation in untransformed cells through the induction of a cell cycle arrest
at late G1 phase. Two critical molecular events underlie TGFß anti-proliferative response: the
transcriptional repression of cMyc and subsequent induction of cell cycle inhibitors like p21
and p15Ink4b [102, 103]. As an immediate early transcription factor proto-oncogenic cMyc
functions as a master regulator of G1-S-cell cycle progression and growth promotion in
pancreatic cancer [93, 103]. cMyc repression by TGFß requires the activation of a Smad3-4
complex to transduce its stimulus into the nucleus. Here, Smad proteins complex with the
transcription factors E2F4/5 and DP1 and corepressor p107 to repress cMyc promoter via
binding to its TGFß-inhibitory element (TIE) [104].
During pancreatic carcinogenesis,  tumor cells change their transcriptional responsiveness
to TGFß and become resistant to the growth inhibitory effects due to functional inactiva‐
tion of the TGFß-Smad pathway [103]. Depending on the cell type and the activation status
of a cell,  TGFß then signals through Smad-independent pathways (e.g. PI3K and MAPK
pathways) to promote the acquisition of a mesenchymal phenotype and stimulate tumor
cell migration [102, 103].
TGFß induces expression of NFATc1 and c2, which accumulate in the nucleus and displace
pre-existing Smad3 repressor complexes from the cMyc TIE element. Mechanistically, NFATc1
binding to the serum responsive element within the proximal cMyc promoter initiates p300-
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dependent histone acetylation rendering the promoter transcriptionally active. Hyperacety‐
lation of the cMyc promoter is required for recruitment of the Ets-like gene 1 (ELK-1), a protein
signaling downstream of Kras, responsible for maximal activation of cMyc [94]. The functional
significance of this pathway is emphasized by restoration of TGFß growth suppressor function
in cancer cells and impaired cMyc expression indicated by reduced tumor growth and G1-
arrest following the pharmacological or genetic inactivation of NFAT proteins [94, 102].
12. NFAT dependent silencing of tumor suppressor genes by formation of
heterochromatin complexes
Activation of NFAT proteins does not only lead to target gene activation in pancreatic cancer,
but also contributes to gene silencing. Being a member of the Ink4 family, p15Ink4b impedes the
activation and function of Cyclin dependent kinases (CDK) 4 and 6 which leads to cell cycle
inhibition and diminished G1-S phase transition [105]. Therefore, p15Ink4b incorporates
important functions as a tumor suppressor in numerous malignancies, most importantly in
pancreatic cancer, where p15Ink4b inactivation by genetic or epigenetic events occurs in over
90% of all tumors [9]. NFATc2 targets p15Ink4b for inducible and sequential heterochromatin
formation and gene silencing. Sequential Chromatinimmunprecipitation revealed that
NFATc2 binding to its putative binding side on the p15Ink4b promoter leads to recruitment of
the histone methyltransferase Suv39H1. Local trimethylation of Lysine 9 on histone 3
(H3K9trime) allows docking of heterochromatin protein 1 y (HP1y) which results in stabili‐
zation of the heterochromatin complex on the p15Ink4b promoter. Conflicting with that,
inactivation of NFATc2 disrupts the repressor complex and results in restoration of p15Ink4b
expression and function [106].
Figure 4. NFAT transcription factors and their impact on hallmarks of cancer




These examples of NFAT dependent alterations in signaling pathways and transcriptional
processes promoting pancreatic carcinogenesis only demonstrate a small insight into how
oncogenic transcription factors contribute to pancreatic cancer development. Via transduction
of EGFR signaling to downstream targets, by cooperation with other pre inflammatory
oncogenes, by modulation of the tumor microenvironment, induction of cell cycle promoting
genes as well as via silencing of important tumor suppressor genes, NFAT proteins are highly
involved in all phases of pancreatic carcinogenesis reaching from early acinar-to-ductal-
metaplasia over establishment of precursor lesions to frank invasive pancreatic adenocarci‐
noma.
As dismal as pancreatic cancer presents itself clinically, as complex and multi-layered are the
histopathological and molecular mechanisms responsible for pancreatic carcinogenesis. As the
molecular main reason for pancreatic cancer development - the constitutive activation of Kras
- evades any pharmacological approach, targeting oncogenic factors like NFAT proteins
represents a promising option approaching success in pancreatic cancer treatment.
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